Not medical advice. Talk to your provider before using any peptide. Full disclaimer
PT-141
Beginner tier: 500 mcg, as needed, max 1 dose/24h, max 8 doses/month · community consensus
Also known as: PT-141, Vyleesi, bremelanotide acetate
The RECONNECT trials enrolled 1,247 women and produced the first FDA approval for a drug that targets sexual desire at the brain level. The PT-141 peptide (bremelanotide, brand name Vyleesi) is a melanocortin-4 receptor agonist, a cyclic heptapeptide that activates MC4R neurons in the hypothalamus to increase arousal and desire on demand. Nausea affects roughly 40% of users on the first dose, and 18% of trial participants discontinued because of side effects. The approval covers premenopausal women with hypoactive sexual desire disorder (HSDD), though off-label use in men with erectile dysfunction has Phase 2 trial support.
What Is PT-141?
Two Phase 3 trials, 1,247 participants, 24 weeks of data, and one FDA approval. That is the clinical foundation behind the PT-141 peptide. Bremelanotide (CAS 189691-06-3) is a cyclic heptapeptide with a molecular weight of 1,025.2 Da, sold under the brand name Vyleesi as a prefilled autoinjector.
The mechanism is unlike anything in the PDE5 inhibitor class. Sildenafil and tadalafil increase blood flow. PT-141 activates melanocortin-4 receptors (MC4R) in the medial preoptic area of the hypothalamus, the region governing sexual motivation. Subcutaneous injection reaches peak plasma concentration within about one hour (Tmax ~1 hour), and functional effects last 6 to 12 hours despite a short 2.7-hour half-life.
The RECONNECT trials [1] showed statistically significant improvements in both desire score and distress score versus placebo at 24 weeks. A 52-week extension confirmed sustained efficacy with no new safety signals. Off-label community use is widespread among both sexes; roughly 500+ Reddit threads document male users reporting subjective benefit, though no Phase 3 trial in men has been completed. The FDA label explicitly states bremelanotide is "not indicated for men."
Cost is a real barrier. Brand Vyleesi runs about $232 per dose at retail. Research-grade vials cost $40 to $80 for a 10 mg vial, but purity and sequence fidelity cannot be verified without independent testing.
How PT-141 Works
PT-141 is a synthetic analog of alpha-melanocyte-stimulating hormone. It binds MC4R, MC3R, and MC1R, though the sexual effects are driven primarily through MC4R activation in the hypothalamus.
MC4R is a G-protein coupled receptor concentrated in the medial preoptic area and paraventricular nucleus. When bremelanotide binds MC4R, it triggers a Gq-coupled signaling cascade that increases intracellular calcium and activates downstream dopaminergic pathways. This directly modulates sexual desire and arousal at the central nervous system level, bypassing peripheral vascular mechanisms entirely.
Subcutaneous bioavailability is approximately 100% per the FDA prescribing information. After injection, plasma concentration peaks at roughly one hour. The elimination half-life sits at 2.7 hours, but receptor occupancy sustains functional effects for 6 to 12 hours. That disconnect between plasma clearance and duration of action is why single on-demand dosing works.
MC1R activation explains the melanocyte-related side effects. Focal hyperpigmentation at injection sites occurred in 1% of Phase 3 participants, and resolution was not confirmed in all cases after stopping. MC3R activation likely contributes to the nausea profile; the area postrema (the brain's emetic center) expresses melanocortin receptors, and 40% nausea incidence tracks with this anatomy.
PT-141 Benefits
- PT-141 benefits center on desire-based sexual function, not vascular mechanics.
- FDA-approved for HSDD in premenopausal women, backed by two Phase 3 randomized controlled trials with 1,247 participants (RECONNECT)[1].
- Works at the brain level through MC4R activation, increasing genuine sexual desire and arousal rather than blood flow alone.
- On-demand dosing with no daily commitment; inject 45 to 60 minutes before activity, with effects lasting 6 to 12 hours.
- Effective for both sexes in community reports; men with PDE5 inhibitor-resistant erectile dysfunction report subjective benefit, supported by Phase 2b trial data [2].
- No tachyphylaxis observed through 76 weeks of total clinical follow-up (24-week trial plus 52-week extension), confirming sustained receptor sensitivity.
- Complementary to PDE5 inhibitors; PT-141 adds central desire while sildenafil or tadalafil handles peripheral blood flow, a combination community users frequently report as complementary.
PT-141: Science vs Community Consensus
FDA-approved 1.75 mg SC on-demand for HSDD in premenopausal women.
Read the evidence (key study, limitations)
RECONNECT Phase 3 (n=1,247) showed statistically significant improvement in desire and distress scores vs. placebo at 24 weeks. 52-week extension confirmed sustained efficacy with no new safety signals. Only 1.75 mg has Phase 3 RCT support: sub-doses have no validated efficacy data.
RECONNECT Phase 3 trials: two randomized double-blind placebo-controlled studies, n=1,247, 24-week primary endpoint, bremelanotide 1.75 mg SC on-demand; PMID 31599840
Approved only for premenopausal women; FDA explicitly not indicated for men; no Phase 3 male trial data; 18% AE-related discontinuation rate; 40% nausea incidence; no sub-dose (500/1000 mcg) RCT efficacy data; focal hyperpigmentation (1%) may be permanent
Widely used off-label by both sexes.
Read the reports (what users report 5, common issues 6)
Effective for central desire and arousal. Nausea is the primary barrier: most users start at 500 mcg to test tolerance before titrating. Men report subjective benefit despite off-label status.
- Genuine central desire and arousal increase, beyond mechanics
- Works for both sexes: off-label in men but widely reported effective
- On-demand only: no daily pill or loading phase required
- Complementary to PDE5 inhibitors (desire + blood flow)
- Desire effects reported even at sub-FDA doses (500–1,000 mcg)
- Nausea in ~40% of users: can be severe enough to ruin the experience on first dose
- Flushing and facial redness noticeable to partners
- Cost barrier: brand Vyleesi ~$230+/dose; research-grade quality is variable
- Focal hyperpigmentation risk at injection sites with frequent use
- Transient BP elevation (usually <12 hours but concerning with CV history)
- Men using off-label have less clinical safety data
Science and community agree on mechanism and efficacy at 1.75 mg. They diverge on dosing: FDA has only one approved dose (1.75 mg), but the community widely uses 500–1,000 mcg sub-doses to manage nausea: a practice with no RCT efficacy validation. Community also extends off-label use to men, which has Phase 2 trial support but no Phase 3 approval.
PT-141 Dosage Guide
Standard reconstitution for a 10 mg vial: add 2 mL bacteriostatic water. That gives you 5,000 mcg per mL, or 50 mcg per unit on a U100 insulin syringe. At 1,750 mcg (the FDA dose), you'll draw 35 units. At 500 mcg (community test dose), draw 10 units. At 1,000 mcg, draw 20 units.
You'll want ondansetron on hand for the first dose. Nausea hits hard the first time and catches people off guard. Inject 45 to 60 minutes before you need it working; don't rush this timing.
One vial at this concentration gives you 5 full doses at 1,750 mcg or up to 20 doses at 500 mcg. Store reconstituted solution refrigerated at 2 to 8 degrees Celsius; use within 30 days. If the solution turns cloudy or shows particles, discard it. Rotate injection sites every time (abdomen and thigh are standard). Keep use to eight doses per month maximum.
PT-141 is on-demand, not cycled in the traditional sense. The FDA-mandated max of 8 doses/month and max 1 dose/24 hours is driven by the transient BP elevation profile and focal hyperpigmentation risk: both cumulative with use frequency. No tachyphylaxis was observed in 52-week clinical trials (PMC6819023), confirming that receptor desensitization is not the limiting factor; safety monitoring is.
- Use frequency exceeding 8 doses/month: pause for a full calendar month
- New or expanding focal hyperpigmentation at injection sites
- Persistent BP elevation extending beyond 12 hours after a dose
- Nausea that does not improve after 4+ doses despite anti-emetic pre-treatment
Or use the universal Peptide Calculator for any peptide.
PT-141 Protocols by Goal
Expected: Statistically significant improvements in sexual desire score and distress score per RECONNECT Phase 3 trial data. Onset ~45–60 min, duration ~6–12 hours.
Monitor: Monitor BP within 12 hours of each dose. Inspect injection sites for focal hyperpigmentation after each use. Avoid use if uncontrolled hypertension.
How to Use PT-141
- 1Reconstitute a 10 mg vial with 2.0 mL bacteriostatic water
Direct the stream down the glass wall, not onto the powder. Swirl gently until dissolved. Solution should be clear and colorless.
- 2Step 2
If pre-treating for nausea, take ondansetron 4 mg by mouth 30 to 60 minutes before the PT-141 injection.
- 3Draw your dose using a U100 insulin syringe
At 2 mL BAC water in a 10 mg vial (5,000 mcg/mL): 10 units equals 500 mcg, 20 units equals 1,000 mcg, 35 units equals 1,750 mcg.
- 4Clean the injection site with an alcohol swab
Abdomen (2 inches from navel) or outer thigh are standard locations.
- 5Step 5
Pinch the skin and insert the needle at a 45 to 90 degree angle using a 29 to 31 gauge, 0.5 inch insulin syringe.
- 6Inject slowly and steadily
Remove the needle and apply light pressure with gauze.
- 7Step 7
Time your injection at least 45 minutes before anticipated activity. Most users find peak effects between 1 and 4 hours after injection.
- 8Step 8
Do not exceed 1 dose per 24 hours or 8 doses per calendar month. Store reconstituted vial refrigerated. Rotate injection sites to reduce hyperpigmentation risk.
Alternative Routes
None: all clinical data based on SC administration
Vyleesi uses a prefilled autoinjector. Research-grade requires reconstitution with BAC water (2 mL for a 10 mg vial = 5,000 mcg/mL).
Bioavailability likely lower than SC; typical intranasal doses 1–2 mg; onset profile unvalidated
Community reports variable efficacy. Used primarily by those who prefer to avoid injections. Not FDA-approved in this form.
PT-141 Stacking Protocols
Works With
Complementary mechanisms: PT-141 increases central desire via MC4R; PDE5i increases genital blood flow via nitric oxide. Community reports a larger combined benefit, especially in men.
PT-141 1,750 mcg SC 45–60 min before; PDE5i at its usual dose. Monitor for additive BP drop.
Community reports enhanced emotional bonding and intimacy when stacked with PT-141. No clinical trial data for this combination.
Oxytocin 24–40 IU intranasal 15–30 min before activity, alongside PT-141.
Pre-treatment reduces PT-141-induced nausea (40% incidence). FDA label acknowledges anti-emetics as a management strategy.
Ondansetron 4 mg PO 30–60 min before PT-141 injection.
Avoid
Both are non-selective melanocortin agonists (MC1R, MC3R, MC4R). Combining adds risk of additive nausea, BP elevation, hyperpigmentation, and spontaneous erections without a meaningful added benefit. Redundant mechanism.
Do not combineBremelanotide significantly reduces naltrexone systemic exposure per FDA label: may destabilize addiction treatment. Direct pharmacokinetic interaction. The label says to avoid oral naltrexone products for alcohol or opioid addiction (section 7.2).
Do not combineBremelanotide causes transient BP elevation (~12h); in patients on antihypertensives or with cardiovascular disease, this can create unpredictable BP fluctuations. Use only with physician oversight.
Estimated Cost
Pricing updated 2026-04-09
PT-141 Side Effects
Nausea is the headline. In the RECONNECT Phase 3 trials, 40% of bremelanotide-treated participants reported nausea versus 1% on placebo. That is not a minor footnote. On the first dose, nausea can be severe enough to cancel the evening. The 18% discontinuation rate due to adverse events reflects this reality.
The nausea comes from melanocortin receptor activation in the area postrema, the same brain region targeted by chemotherapy-induced emesis. Pre-treatment with ondansetron (Zofran) 4 mg taken orally 30 to 60 minutes before injection is the most common community workaround. Eating a light meal and staying hydrated also helps. Most users report that nausea decreases significantly after two to four doses as MC4R partially adapts.
Flushing occurred in about 20% of participants. Facial redness can be noticeable to partners. Headache affected 11%.
Blood pressure elevation is transient but clinically important. Bremelanotide raises systolic and diastolic BP for up to 12 hours after each dose. For anyone with uncontrolled hypertension or cardiovascular disease, this is a hard contraindication per the FDA label. Even in healthy users, blood pressure should be monitored, particularly within the first 12 hours.
Focal hyperpigmentation at injection sites was documented in 1% of Phase 3 participants. This comes from MC1R activation stimulating melanocytes. The FDA label warns that resolution was not confirmed in all cases after stopping. Rotating injection sites and limiting use to eight or fewer doses per month appears to minimize this risk based on community experience.
Drug interactions matter here. Bremelanotide significantly reduces systemic exposure of oral naltrexone, a pharmacokinetic interaction serious enough that the FDA label says to avoid the combination (section 7.2). Patients on naltrexone for alcohol or opioid use disorder must avoid PT-141. Bremelanotide may also slow gastric emptying, delaying absorption of other oral medications.
Pregnancy is not a label contraindication (section 4), but the label does not recommend use in pregnancy. Animal studies point to possible fetal harm, so it advises effective contraception and stopping if pregnancy is suspected (sections 8.1 and 8.3). The label does not list hypersensitivity as a contraindication; stop if an allergic reaction occurs. Hepatic impairment raises exposure 1.2-fold in mild and 1.7-fold in moderate disease (section 12.3), yet the label recommends no dose adjustment for mild to moderate (Child-Pugh A and B) impairment. Severe (Child-Pugh C) impairment was not studied; the label says use with caution (section 8.7).
When to stop: discontinue if blood pressure elevation persists beyond 12 hours, if focal hyperpigmentation appears, if nausea remains unmanageable after multiple doses with anti-emetic support, or if no improvement is seen after 8 weeks of use (per FDA label guidance).
Common Issues & Solutions
Severe nausea on first dose: Pre-treat with ondansetron (Zofran) 4 mg PO 30–60 min before injection. Inject slowly. Eat a light meal and stay hydrated. Nausea typically decreases with repeat dosing as MC4R partially adapts. Starting at 500 mcg test dose also reduces severity.
No effect at sub-FDA doses (500–1,000 mcg): Only 1.75 mg (1,750 mcg) has RCT efficacy evidence. If there is no response at lower doses, increase to 1,750 mcg before concluding non-response. Do not continue sub-doses assuming equivalent efficacy: no clinical data supports this.
Focal hyperpigmentation at injection site: Rotate injection sites every use. Keep use ≤8 doses/month. Avoid sun exposure on recently injected areas. Hyperpigmentation may persist after stopping in some patients (1% in Phase 3 trials). Consult a dermatologist if darkening progresses.
Transient BP elevation with palpitations or lightheadedness: Effects usually resolve within 12 hours per FDA label. Lie down if symptomatic. Do not use with uncontrolled hypertension. Avoid stacking with PDE5 inhibitors if BP history is a concern: additive hypotension possible in that combination.
Drug interaction concern with naltrexone: Bremelanotide significantly reduces oral naltrexone systemic exposure. Patients on naltrexone for alcohol or opioid use disorder must not combine: risk of destabilizing addiction treatment. The Vyleesi label says to avoid this combination (section 7.2, Drug Interactions).
Ask AI about this page
Ask AI for a second opinion on PT-141 dosing and side effects
Contraindications
- Uncontrolled hypertension or known cardiovascular disease
- Pregnancy or breastfeeding: not label contraindications, but the label does not recommend use in pregnancy, says to stop if pregnancy is suspected (sections 8.1 and 8.3) and has no human milk data (section 8.2)
- Known hypersensitivity to bremelanotide or any excipient: not a label contraindication (section 4 names only uncontrolled hypertension and known cardiovascular disease)
- Concurrent use with oral naltrexone-containing products
- Severe hepatic impairment (Child-Pugh C): not studied, use with caution (section 8.7); no dose adjustment for mild to moderate (Child-Pugh A and B)
Drug Interactions
- Naltrexone (oral): bremelanotide significantly decreases naltrexone systemic exposure; avoid concurrent use with naltrexone-containing products for alcohol or opioid addiction
- Indomethacin: bremelanotide may reduce absorption of co-administered indomethacin
- Antihypertensives: monitor blood pressure; bremelanotide causes transient BP elevation
- Other oral medications: bremelanotide may slow gastric emptying and delay absorption of co-administered oral drugs
- Bremelanotide significantly reduces naltrexone systemic exposure per FDA label: may destabilize addiction treatment. Direct pharmacokinetic interaction. The label says to avoid oral naltrexone products for alcohol or opioid addiction (section 7.2).
Product Quality
FDA-approved brand (Vyleesi autoinjector) is verified and the safest option. However, the majority of community use involves unregulated research-grade vials where purity, sequence fidelity, and contamination cannot be confirmed without independent testing.
- Vyleesi autoinjector (Cosette Pharmaceuticals) is the only FDA-verified formulation: use it if accessible
- For research-grade vials: a certificate of analysis (COA) showing HPLC purity ≥98% is the usual benchmark
- Verify peptide by mass spec: bremelanotide MW 1025.2 Da; cyclic heptapeptide
- Products without third-party testing documentation have unverified purity
- Reconstituted peptide should be clear and colorless: discard if cloudy or particulate
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Blood pressure | Baseline before first dose; within 12 hours of each dose if cardiovascular history present | Systolic rise <30 mmHg from baseline; avoid use if uncontrolled hypertension |
| Skin inspection: injection sites | After each use; monthly overall check | Not listed |
| Efficacy self-assessment | After 8 weeks of use (per FDA discontinuation guidance) | Not listed |
Bremelanotide causes transient BP elevation documented in FDA Phase 3 trials; resolves within 12 hours
Focal hyperpigmentation from MC1R activation reported in 1% of Phase 3 patients; may be permanent in some cases
FDA label recommends stopping after 8 weeks if no meaningful improvement; on-demand use requires periodic reassessment
PT-141 Before and After
Onset of effects within 45-60 minutes of SC injection. Nausea is most common on first use. Flushing and warmth may occur as MC4R activation begins.
Nausea typically decreases with repeated use. Patients learn optimal timing relative to activity. Effects last approximately 6-12 hours after dosing.
Side effect profile stabilizes. Patients establish personal effective dose within the 0.5-1.75mg range. On-demand pattern becomes routine.
Consistent on-demand use as needed, up to 8 doses per month. No tachyphylaxis observed in clinical trials lasting 24 weeks. Blood pressure should be monitored periodically.
What to Expect
0 to 60 minutes (first dose): Peak plasma concentration hits around the one-hour mark. MC4R activation starts driving central arousal within 45 to 60 minutes. Nausea often arrives before the desired effects do, affecting 40% of users on that first injection. Flushing, warmth, and tingling are common early signs. Blood pressure may rise transiently.
1 to 6 hours (active window): This is the peak effect window. Most users report strongest desire and arousal between one and four hours post-injection. The half-life is 2.7 hours, but receptor occupancy keeps functional effects going for 6 to 12 hours depending on the individual. Nausea typically fades by the two to three hour mark. Flushing may stick around longer.
6 to 12 hours (resolution): Blood pressure normalizes within 12 hours per FDA label data. Most users feel back to baseline by this point. Some report mild residual headache or fatigue. No hangover effect is typical.
Doses 2 through 8 (first month): Nausea drops significantly after the first two to four doses for most people. Personal effective dose becomes clear, usually landing between 1,000 and 1,750 mcg. No tachyphylaxis was observed at 1.75 mg over 24 weeks in Phase 3 trials; a 52-week extension (PMC6819023) confirmed sustained efficacy.
Month 2 onward (ongoing use): Long-term safety was confirmed through 76 total weeks of clinical follow-up with no new safety signals. Most users settle into an on-demand pattern, reserving PT-141 for specific occasions due to nausea management overhead and cost. Focal hyperpigmentation risk increases with use frequency; rotating injection sites is important.
Detailed Timeline: Science vs Community
Tmax ~1 hour. MC4R activation begins driving central arousal. Nausea onset typically within 1 hour (40% incidence). BP may transiently rise.
Variable first-dose experience. Many users report strong nausea before effects kick in. Some feel warmth, flushing, and tingling. Sexual arousal and desire often noticeable by 45–60 min.
Maximum plasma concentration ~1 hour. Effects expected within this window. Half-life 2.7 hours. Functional duration extends 6–12 hours based on receptor occupancy.
Most users report peak desire and arousal effects between 1–4 hours. Effect duration varies widely: some report 6–8 hours, others 12+ hours.
BP elevation resolves within 12 hours per FDA label. Plasma concentrations approaching elimination phase.
Most users feel back to normal by 12 hours. Some report residual mild fatigue or headache. No hangover effect typically reported.
No tachyphylaxis observed at 1.75 mg over 24-week Phase 3 trials. Continued efficacy sustained through 52-week extension (PMC6819023).
Most users report nausea decreases significantly after 2–4 doses. Personal effective dose becomes clear. Many stabilize at 1,000–1,750 mcg.
Long-term safety confirmed through 76 weeks total (24-week trial + 52-week extension) with no new safety signals. Max 8 doses/month per FDA.
Consistent on-demand use. Most users reserve for high-priority occasions due to nausea management overhead and cost. Some note continued mild improvement in baseline desire over time.
Pharmacokinetics
Source: FDA Prescribing Information (Vyleesi), Section 12.3
Pharmacokinetics: Active Dose Over Time
t½ = ~2.7 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is PT-141 Legal?
Bremelanotide received FDA approval in June 2019 under the brand name Vyleesi (NDA 210557) for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is manufactured by Cosette Pharmaceuticals as a prefilled single-dose autoinjector delivering 1.75 mg subcutaneously.
The FDA label explicitly states bremelanotide is "not indicated in men or in postmenopausal women." Off-label prescribing by licensed physicians is legal but carries reduced clinical safety data compared to the approved population.
Research-grade bremelanotide is sold online as lyophilized powder for research purposes. These products are not FDA-approved for human use. Quality varies; certificates of analysis with HPLC purity data and mass spectrometry confirmation (MW 1,025.2 Da) are the only record of what a batch contains.
PT-141 does not appear on the World Anti-Doping Agency (WADA) prohibited list. Peptide Schedule provides information for research and educational purposes only. This content does not constitute medical advice, and readers should consult a licensed healthcare provider before using any peptide.
Who Should Consider PT-141
- Premenopausal women with hypoactive sexual desire disorder (HSDD)
- Men with erectile dysfunction unresponsive to PDE5 inhibitors
- Individuals seeking desire-based (not blood-flow-based) treatment
- Patients who cannot tolerate PDE5 inhibitors
Related Peptides
What Changed for PT-141
- Safety
Corrected Oct 20, 2026: pregnancy is a label caution for PT-141, not a contraindication, per the Vyleesi label, sections 4, 8.1 and 8.3.
Before: Pregnancy is a contraindication. After: Pregnancy is not a label contraindication (section 4), but the label does not recommend use in pregnancy (sections 8.1 and 8.3).
What this does not mean: The caution stands. Animal studies point to possible fetal harm, so the label advises effective contraception and stopping if pregnancy is suspected. Section 4 lists only uncontrolled hypertension and known cardiovascular disease.
Source: Vyleesi (bremelanotide injection) prescribing information, sections 4, 8.1, 8.2 and 8.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 20, 2026: pregnancy and breastfeeding are not PT-141 label contraindications, per the Vyleesi label, sections 4 and 8.1 to 8.3.
Before: Pregnancy or breastfeeding After: Pregnancy or breastfeeding: not label contraindications, but the label does not recommend use in pregnancy, says to stop if pregnancy is suspected (sections 8.1 and 8.3) and has no human milk data (section 8.2)
What this does not mean: Pregnancy stays on the list as a caution: the label does not recommend use in pregnancy and says to stop if pregnancy is suspected. It has no data on bremelanotide in human milk.
Source: Vyleesi (bremelanotide injection) prescribing information, sections 4, 8.1, 8.2 and 8.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 20, 2026: hypersensitivity is not a PT-141 label contraindication, per the Vyleesi label, section 4.
Before: Known hypersensitivity to bremelanotide or excipients is a contraindication. After: The label does not list hypersensitivity as a contraindication; stop if an allergic reaction occurs.
What this does not mean: The allergy caution stays: stop PT-141 if an allergic reaction occurs. Section 4 names only uncontrolled hypertension and known cardiovascular disease.
Source: Vyleesi (bremelanotide injection) prescribing information, section 4 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 20, 2026: known hypersensitivity stays listed for PT-141 as a caution, not a label contraindication, per the Vyleesi label, section 4.
Before: Known hypersensitivity to bremelanotide or any excipients After: Known hypersensitivity to bremelanotide or any excipient: not a label contraindication (section 4 names only uncontrolled hypertension and known cardiovascular disease)
What this does not mean: An allergy to bremelanotide or an excipient is still a reason not to use it. The label simply does not name it; section 4 lists uncontrolled hypertension and known cardiovascular disease.
Source: Vyleesi (bremelanotide injection) prescribing information, section 4 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 20, 2026: PT-141 needs no dose adjustment in mild to moderate hepatic impairment, per the Vyleesi label, sections 8.7 and 12.3.
Before: Moderate to severe hepatic impairment increases drug exposure and should prompt dose adjustment or avoidance. After: Exposure rises 1.2-fold (mild) and 1.7-fold (moderate), yet the label recommends no dose adjustment for mild to moderate impairment; severe was not studied, use with caution (section 8.7).
What this does not mean: Exposure still rises 1.2-fold in mild and 1.7-fold in moderate impairment. Severe (Child-Pugh C) impairment was not studied, and the label says use with caution there.
Source: Vyleesi (bremelanotide injection) prescribing information, sections 8.7 and 12.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 20, 2026: only severe hepatic impairment carries a PT-141 caution; mild to moderate needs no dose change, per the Vyleesi label, section 8.7.
Before: Hepatic impairment (moderate to severe): increased drug exposure After: Severe hepatic impairment (Child-Pugh C): not studied, use with caution (section 8.7); no dose adjustment for mild to moderate (Child-Pugh A and B)
What this does not mean: Severe (Child-Pugh C) impairment was not studied, so the label says use with caution. The page had listed moderate to severe impairment as a contraindication.
Source: Vyleesi (bremelanotide injection) prescribing information, sections 8.7 and 12.3 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 19, 2026: PT-141 with oral naltrexone is a combination to avoid, not a listed contraindication, per the Vyleesi label, section 7.2.
Before: a pharmacokinetic interaction serious enough that the FDA lists it as a contraindication. After: a pharmacokinetic interaction serious enough that the FDA label says to avoid the combination (section 7.2).
What this does not mean: The interaction is unchanged: PT-141 may significantly lower oral naltrexone exposure, so people treated for alcohol or opioid addiction should avoid it. Only the label section the page named was wrong.
Source: Vyleesi (bremelanotide injection) prescribing information, sections 4 and 7.2 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 19, 2026: oral naltrexone is a drug interaction to avoid with PT-141, not a contraindication, per the Vyleesi label, sections 4 and 7.2.
Before: Listed as a contraindication in FDA prescribing information. After: The label says to avoid oral naltrexone products for alcohol or opioid addiction (section 7.2).
What this does not mean: The advice stands: avoid PT-141 with oral naltrexone products for alcohol or opioid addiction, since it may cut naltrexone exposure. The label's contraindications are uncontrolled hypertension and known cardiovascular disease.
Source: Vyleesi (bremelanotide injection) prescribing information, sections 4 and 7.2 (openFDA label record, SPL version 1, effective Nov 13, 2025) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 202610 Citations
References
- [1]RECONNECT: Bremelanotide for the Treatment of HSDD: Two Randomized Phase 3 Trials (RECONNECT) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Phase 2b Dose-Ranging Study of Bremelanotide (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]FDA NDA 210557
Additional References
- Bremelanotide: First Approval (Drugs) (opens in a new tab)PubMed 31429064PubMed
- RECONNECT Phase 3 Subgroup Analyses (opens in a new tab)PubMed 35230162PubMed
- Vyleesi (Bremelanotide) FDA Prescribing Information (opens in a new tab)FDA Label
- PMC6819023 (PMC6819023) (opens in a new tab)PubMed
- Should Bremelanotide Be Considered for Treatment of Sexual Arousal/Desire in Men? (J Clin Psychopharmacol 2026) (opens in a new tab)PubMed 41960633PubMed
- Female Sexual Desire, Arousal, Orgasmic Dysfunctions: Meta-Analysis of Pharmacologic Interventions (J Minim Invasive Gynecol 2026) (opens in a new tab)PubMed 40543759PubMed
- Novel Pharmacologic Treatments of Female Sexual Dysfunction (Clin Obstet Gynecol 2025) (opens in a new tab)PubMed 39846877PubMed
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is PT-141?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 500+. Community mentions on Reddit: ~500+ threads in r/Peptides, r/erectiledysfunction, r/sex. Open r/Peptides (opens in a new tab).
102 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.